Antibodies and antibody-derived macromolecules have established themselves as the
mainstay in protein-based therapeutic molecules (biologics). Our knowledge of the structure …

Antibody–drug conjugates (ADCs) are targeted immunoconjugate constructs that integrate
the potency of cytotoxic drugs with the selectivity of monoclonal antibodies, minimizing …

Antibodies and Fc-fusion antibody-like proteins have become successful biologics
developed for cancer treatment, passive immunity against infection, addiction, and …

Understanding the impact of glycosylation and keeping a close control on glycosylation of
product candidates are required for both novel and biosimilar monoclonal antibodies (mAbs) …

Antibody-based proteins have become an important class of biologic therapeutics, due in
large part to the stability, specificity, and adaptability of the antibody framework. Indeed …

Antibodies produced in response to a foreign antigen are characterized by polyclonality, not
only in the diverse epitopes to which their variable domains bind but also in the various …

It has been over four decades since the development of monoclonal antibodies (mAbs)
using a hybridoma cell line was first reported. Since then more than thirty therapeutic …

Virus-like particles (VLPs) have been shown to be strong activators of dendritic cells (DCs).
DCs are the most potent antigen presenting cells (APCs) and their activation prompts the …

IgG antibodies are secreted from B cells and bind to a variety of pathogens to control
infections as well as contribute to inflammatory diseases. Many of the functions of IgGs are …

Glycosylation of the Fc region of IgG has a profound impact on the safety and clinical efficacy
of therapeutic antibodies. While the biantennary complex-type oligosaccharide attached to …